Micromet Has Started A New Phase 2 Trial With Adecatumumab In Colorectal Cancer Patients

News — By on April 14, 2009 at 12:46 pm

BETHESDA, Md. — Micromet, Inc., a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced the commencement of a randomized, controlled phase 2 trial of its human anti-EpCAM IgG1 antibody adecatumumab (MT201) for the treatment of patients with colorectal cancer (CRC) after complete resection of liver metastases. The trial has three arms comparing single agent adecatumumab to combination chemotherapy (FOLFOX: 5-FU/Leucovorin plus Oxaliplatin), and to FOLFOX followed by adecatumumab. The primary endpoint will be the disease-free survival rate at one year. “The relapse of colorectal cancer patients with liver metastases still re…

Please read the complete article and let us know what you think below.

Leave a Reply

Trackbacks

Leave a Trackback